Related references
Note: Only part of the references are listed.Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
Zhendong Song et al.
ACTA PHARMACEUTICA SINICA B (2021)
Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review
Rati Kailash Prasad Tripathi et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2021)
Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
Xiangbo Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Targeting SHP2 as a therapeutic strategy for inflammatory diseases
Yang Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2)
Se Jeong Kwon et al.
MOLECULES (2021)
Novel PROTACs for degradation of SHP2 protein
Mengzhu Zheng et al.
BIOORGANIC CHEMISTRY (2021)
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
Yihui Song et al.
ACTA PHARMACEUTICA SINICA B (2021)
Strategies to overcome drug resistance using SHP2 inhibitors
Meng Liu et al.
ACTA PHARMACEUTICA SINICA B (2021)
Targeted Degradation of the Oncogenic Phosphatase SHP2
Vidyasiri Vemulapalli et al.
BIOCHEMISTRY (2021)
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
D. Lucas Kerr et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2021)
SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice
Wen Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Therapeutic potential of targeting SHP2 in human developmental disorders and cancers
Dadong Shen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Mingliang Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Xinrui Yuan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
Yuting Sun et al.
CANCER RESEARCH (2020)
Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders
Kai Tang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
Matthew J. LaMarche et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement
Yelena Mostinski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types
Cijo George Vazhappilly et al.
INVESTIGATIONAL NEW DRUGS (2019)
Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
Jeffrey T. Bagdanoff et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
Patrick Sarver et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2
Xiaoqin Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Dual Allosteric Inhibition of SHP2 Phosphatase
Michelle Fodor et al.
ACS CHEMICAL BIOLOGY (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
Ricardo A. P. Padua et al.
NATURE COMMUNICATIONS (2018)
Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
Xiu-Man Zhou et al.
FRONTIERS IN IMMUNOLOGY (2018)
Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment
Jingjing Xie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2
Jonathan R. LaRochelle et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Jorge Garcia Fortanet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2
Cynthia M. Chio et al.
BIOCHEMISTRY (2015)
Selective Inhibitors of the Protein Tyrosine Phosphatase SHP2 Block Cellular Motility and Growth of Cancer Cells in vitro and in vivo
Stefanie Grosskopf et al.
CHEMMEDCHEM (2015)
Exploring the Existing Drug Space for Novel pTyr Mimetic and SHP2 Inhibitors
Rongjun He et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2
Chuan Chen et al.
SCIENTIFIC REPORTS (2015)
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Wen-Qing Huang et al.
CURRENT CANCER DRUG TARGETS (2014)
Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
Li-Fan Zeng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Identification of Cryptotanshinone as an Inhibitor of Oncogenic Protein Tyrosine Phosphatase SHP2 (PTPN11)
Wei Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Bing Yu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2
Dongping Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs
Latanya M. Scott et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
SHP2 Is a Target of the Immunosuppressant Tautomycetin
Sijiu Liu et al.
CHEMISTRY & BIOLOGY (2011)
Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112
Liwei Chen et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
Xian Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Gordon Chan et al.
CANCER AND METASTASIS REVIEWS (2008)
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds
Harshani R. Lawrence et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors
D. Miyamoto et al.
ONCOGENE (2008)
Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking
Klaus Hellmuth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual T lymphocytes
Holger Hoff et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor
Liwei Chen et al.
MOLECULAR PHARMACOLOGY (2006)
An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival
WT Yang et al.
DEVELOPMENTAL CELL (2006)
SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor
S Ali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
YM Agazie et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors
CJ Wu et al.
ONCOGENE (2001)
Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines
MK Pathak et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
